Empagliflozin and the risk of Gout: Analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

被引：0
|
作者：
Koeneman, Lisette [1 ]
Tesfaye, Helen [2 ]
Paik, Julie M. [2 ]
Zabotka, Luke E. [2 ]
Htoo, Phyo T. [2 ]
Schmedt, Niklas [3 ]
Seman, Leo [4 ,5 ]
Wexler, Deborah J. [6 ,7 ]
Patorno, Elisabetta [2 ]
机构：
[1] Lilly Deutschland GmbH, Global Med Affairs, Bad Homburg, Germany
[2] Harvard Med Sch, Dept Med, Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA 02115 USA
[3] Boehringer Ingelheim Int GmbH, Dept Global Epidemio, Ingelheim, Germany
[4] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[5] Clin Dev & Med Affairs, Ridgefield, CT USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA
[7] MGH Diabet Ctr, Div Endocrinol, Boston, MA USA
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P21-02
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [1] Empagliflozin and the Risk of Gout-Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Tesfaye, Helen
    Paik, Julie M.
    Zabotka, Luke
    Htoo, Phyo T.
    Schmedt, Niklas
    Koeneman, Lisette
    Seman, Leo J.
    Wexler, Deborah J.
    Patorno, Elisabetta
    DIABETES, 2023, 72
  • [2] Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study
    Tesfaye, Helen
    Wang, Katherine M.
    Zabotka, Luke E.
    Wexler, Deborah J.
    Schmedt, Niklas
    Koeneman, Lisette
    Seman, Leo
    Paik, Julie M.
    Patorno, Elisabetta
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2024, 39 (10) : 1870 - 1879
  • [3] COMPARATIVE EFFECTIVENESS AND SAFETY OF EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica M.
    Najafzadeh, Mehdi
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    Bessette, Lily G.
    Kulldorff, Martin
    Schneeweiss, Sebastian
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 683 - 683
  • [4] Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Htoo, Phyo T.
    Tesfaye, Helen
    Paik, Julie M.
    Wexler, Deborah J.
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz F. Fazeli
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [5] Effectiveness and safety of empagliflozin in routine care: Results from the empagliflozin comparative effectiveness and safety (emprise) study
    Htoo, Phyo
    Tesfaye, Helen
    Paik, Julie
    Wexler, Deborah
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 40 - 41
  • [6] Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Wexler, Deborah J.
    Glynn, Robert J.
    Bessette, Lily G.
    Paik, Julie M.
    Najafzadeh, Mehdi
    Brodovicz, Kimberly G.
    Deruaz-Luyet, Anouk
    Schneeweiss, Sebastian
    DIABETES OBESITY & METABOLISM, 2022, 24 (03): : 442 - 454
  • [7] Comparative effectiveness of empagliflozin in reducing total cardiovascular events in the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Desai, Rishi J.
    Glynn, Robert
    Everett, Brendan
    Schneeweiss, Sebastian
    Wexler, Deborah
    Luyet, Anouk Derauz
    Vedin, Ola
    Brodovicz, Kimberly G.
    Pawar, Ajinkya
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 42 - 43
  • [8] Empagliflozin and the Risk of Atherosclerotic Events and Hospitalization for Heart Failure: Updated Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Htoo, Phyo
    Tesfaye, Helen
    Najafzadeh, Mehdi
    Schneeweiss, Sebastian
    Jawaid, Dureshahwar
    Wexler, Deborah J.
    Glynn, Robert
    Koeneman, Lisette
    Luyet, Anouk Deruaz
    Paik, Julie
    Patorno, Elisabetta
    CIRCULATION, 2021, 144
  • [9] COMPARATIVE EFFECTIVENESS OF EMPAGLIFLOZIN IN REDUCING TOTAL CARDIOVASCULAR EVENTS IN THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
    Desai, Rishi
    Glynn, Robert
    Everett, Brendan
    Schneeweiss, Sebastian
    Wexler, Deborah
    Deruaz-Luyet, Anouk
    Vedin, Ola
    Brodovicz, Kimberly
    Pawar, Ajinkya
    Patorno, Elisabetta
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 543 - 543
  • [10] Effectiveness and safety of empagliflozin in routine care patients: interim results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Bessette, L.
    Franklin, J.
    Najafzadeh, M.
    Wexler, D.
    Deruaz-Luyet, A.
    Brodovicz, K.
    Schneeweiss, S.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S145 - S146
12345